Reporting from EULAR 2024: Adalimumab Biosimilar MSB11022 Demonstrates Comparable Safety, Efficacy in RA
Among patients with rheumatoid arthritis (RA), treatment with the adalimumab biosimilar MSB11022 was shown to sustain the prior benefits reported in previous adalimumab treatment, according to data presented at the 2024 European Congress of Rheumatology (EULAR). In some cases, treatment with the biosimilar led to greater improvements while maintaining a safety profile in line with previously described biosimilars.
“MSB11022 is a biosimilar of adalimumab that has been shown to have comparable bioequivalence, safety, tolerability, and immunogenicity profiles to the reference drug in healthy volunteers, patients with psoriasis, or patients with moderate-severe rheumatoid arthritis,” wrote a team of investigators led by Javier Garcia Miguel, MD, PhD, associated with the rheumatology department of Sagrat Cor University Hospital, Spain. “This is the first study conducted under clinical practice conditions evaluating the switch from adalimumab to MSB11022 in patients with rheumatoid arthritis.”
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
